☰ Show/Hide Menu

Proprietary Portfolio

You are here

  1. Home
  2. Pipeline
  3. Proprietary Portfolio

The continued success of its partnered discovery segment provides MorphoSys with the adequate resources to channel substantial investment into proprietary R&D. Its in-house development organization focuses on the development of promising therapeutic antibody candidates in the area of inflammation and oncology. Learn more about the our programs which are in clinical evaluation:

MorphoSys is committed to expanding its proprietary portfolio. We believe that each program has a substantial therapeutic potential.

Dr. Arndt Schottelius
Chief Development Officer

Clinical Programs

MOR208

MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.
Further Information

MOR202

In preclinical studies, MOR202 mediated antibody-dependent cell-mediated cytotoxicity in MM cells derived from patients in vitro.
Further Information

MOR103/GSK3196165

MOR103 (GSK3196165) is a fully human HuCAL antibody directed against GM-CSF (granulocytemacrophage-colony stimulating factor). MOR103 is being developed in the area of inflammatory diseases.
Further Information

MOR209/ES414

MOR209/ES414 is a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer. The immunotherapeutic protein activates the patients’ T-cell immunity specifically against prostate cancer cells expressing Prostate Specific Membrane Antigen (PSMA), an antigen commonly overexpressed in this tumor.
Further Information

MOR106

MOR106 is a human IgG1 monoclonal antibody for treatment of inflammatory diseases.
Further Information